Embla Medical: Building a Better Future for Mobility

Embla Medical is a leading global medical technology company that helps people with mobility challenges live more active and independent lives. Through well known brands such as Össur, College Park, Fior & Gentz, and ForMotion, the company develops prosthetic limbs, orthopedic braces, and other mobility solutions while also operating a growing network of specialized clinics that fit and support patients. Backed by continuous innovation, favorable demographic trends, and a growing focus on improving patient outcomes, Embla Medical aims to reach more people with its mobility solutions while driving long term growth. The question remains: Does this global mobility leader deserve a spot in your portfolio?

This is not financial advice. I am not a financial advisor, and I publish these analyses to document my own research and share my thoughts with readers and followers. If you are considering investing in any of the companies or ideas discussed, you should always do your own research and, if necessary, consult a qualified financial professional. All investing involves risk, and you may lose some or all of the money you invest.

For full disclosure, I do not own shares in Embla Medical at the time of writing this analysis. I publicly share my investment portfolio, including all of my current holdings and changes I make over time. If you are interested in seeing what I currently invest in and learning how you can follow or copy my portfolio, you can read more here.

View my portfolio and learn how to copy it.

The Business

Embla Medical was founded in Iceland in 1971 by Össur Kristinsson, a prosthetist who had lost part of his own leg and developed a more comfortable silicone interface for prosthetic limbs. Originally known as Össur, the company has grown from a small Icelandic prosthetics business into a leading global provider of mobility solutions for people living with limb loss, neurological conditions, osteoarthritis, injuries, and other conditions that restrict movement. The listed parent company adopted the name Embla Medical in 2024 to reflect its development into a broader group with several brands and a growing presence across products, clinical services, and patient care. Össur remains its largest and best known brand, while the group also includes College Park, Fior & Gentz, Streifeneder ortho.production, and the ForMotion network of patient care clinics. Embla Medical operates in more than 40 countries and employs approximately 4,500 people worldwide. Its purpose is to improve people’s mobility and help them live what the company calls a Life Without Limitations. The business is organized into three segments: Prosthetics & Neuro Orthotics, Bracing & Supports, and Patient Care. In 2025, Prosthetics & Neuro Orthotics accounted for 51% of sales, Patient Care represented 33%, and Bracing & Supports contributed the remaining 16%. Geographically, EMEA represented 49% of sales, the Americas accounted for 43%, and APAC contributed 8%, giving the company broad exposure across developed healthcare markets and a growing position in emerging regions. The Prosthetics & Neuro Orthotics segment is Embla Medical’s largest and fastest growing business. Through the Össur and College Park brands, the company develops and manufactures components for lower and upper limb prostheses, including artificial feet, knees, hands, fingers, liners, sockets, and connecting components. Its portfolio ranges from relatively simple mechanical products for people with limited mobility to advanced bionic devices that use sensors, software, motors, and microprocessors to respond to the user’s movements. Products such as the Navii bionic knee, the Power Knee, the College Park Icon knee, and the Odyssey iQ foot are designed to help users walk more naturally, navigate slopes and stairs, recover from stumbles, and participate in a wider range of everyday activities. Embla Medical also offers specialized products for children, highly active users, and people with lower activity levels who prioritize stability, safety, and comfort. This broad product portfolio allows the company to serve patients across different ages, activity levels, medical needs, and reimbursement categories. The global prosthetics product market is estimated by Embla Medical at approximately USD 2 billion, and the company estimates that it holds a market share of around 25%, making it the second largest global participant.  Many prosthetic components need to be maintained or replaced periodically because of wear, changes in the patient’s body, or improvements in available technology, creating a recurring source of demand rather than a single one time purchase. The neuro orthotics business is operated primarily through Fior & Gentz and provides premium mechanical and electronically controlled joints used in custom orthotic devices. These solutions are designed for people whose walking ability has been affected by conditions such as stroke, multiple sclerosis, cerebral palsy, spinal cord injury, or other neurological disorders. Rather than replacing a missing limb, neuro orthotics support and guide an existing leg or joint to improve stability and movement. The company’s products are used in ankle foot orthoses and knee ankle foot orthoses that are individually designed and fitted to each patient. Embla Medical estimates the market it serves within neuro orthotics at approximately USD 500 million and its current market share at around 6%. Embla Medical can use its existing relationships with clinics, clinicians, and payers to introduce Fior & Gentz products into additional countries, giving the company an opportunity to grow both the market and its share within it. The Bracing & Supports segment is operated under the Össur brand and provides products for people recovering from injuries, surgery, or musculoskeletal conditions, as well as people living with osteoarthritis. The portfolio includes braces and supports for the knee, hip, spine, ankle, foot, wrist, and other joints. Its injury solutions stabilize joints and support the healing of bones, ligaments, and soft tissue following fractures, surgery, or acute injuries. Its osteoarthritis products are designed to relieve pain and improve mobility without surgery by redistributing pressure away from the damaged part of a joint. The best known products include the Unloader range of knee braces and the Unloader Hip, which are designed for people with osteoarthritis in the knee or hip. Embla Medical estimates that the part of the global Bracing & Supports market in which it competes is worth approximately USD 3 billion and that it holds a market share of around 5%. Patient Care is Embla Medical’s third business segment and provides clinical services directly to people who require prosthetic or orthotic solutions. The company operates a global network of Orthotic & Prosthetic clinics under the ForMotion brand, where trained clinicians assess patients, recommend appropriate solutions, manufacture or customize individual components, fit the finished device, and provide ongoing adjustments and care. Unlike an ordinary medical product that can be purchased and used immediately, a prosthesis or custom orthosis normally requires close cooperation between the patient, the clinician, and the manufacturer. Each patient has a different body shape, level of mobility, medical condition, and personal objective, which means that even standardized components must often be combined with individually fabricated parts. By operating its own clinics, Embla Medical participates directly in this important part of the value chain and develops a better understanding of patient needs, clinical workflows, reimbursement requirements, and the performance of its products in real world use. The global Patient Care market is estimated at approximately USD 15 billion, making it substantially larger than the product markets in which Embla Medical operates. However, it is also highly fragmented, and Embla Medical estimates that it is only the third or fourth largest provider, with a market share of around 2%. Embla Medical’s business model connects product development, manufacturing, sales, clinical care, and patient feedback. The company develops both standardized and customized mobility products, manufactures them across facilities in Iceland, Germany, Scotland, the United States, and Mexico, and distributes them primarily through its own sales organization. Its customers include independent Orthotic & Prosthetic clinics, hospitals, surgery centers, rehabilitation providers, and other healthcare professionals. These providers fit the products to patients and normally seek reimbursement from public healthcare systems or private insurance companies. Approximately 90% of Embla Medical’s products and services are reimbursed by third parties, which makes demand less dependent on the patient’s personal spending capacity and provides greater stability than markets in which customers must pay the full cost themselves. Embla Medical has gradually shifted from being primarily a manufacturer of individual products toward becoming a more patient focused provider of complete mobility solutions. A prosthetic leg, for example, is not a single product but a combination of components such as a foot, knee, liner, socket, adapters, and software that must work together and be adjusted to the individual patient. The customized socket that connects the remaining part of the limb to the prosthesis is particularly important because poor fit can cause pain, skin problems, instability, and reduced use of the prosthesis. Traditionally, producing this customized part has involved manual measurements, plaster casting, and labor intensive fabrication performed by skilled clinicians and technicians. Embla Medical is investing in digital scanning, direct socket technology, centralized fabrication, computer aided design, and 3D printing to make these processes more efficient, consistent, and scalable. These technologies allow a clinician to digitally capture the shape of a patient’s limb, design the required component, and manufacture it with less manual work. This can reduce production time, improve consistency, and allow clinicians to spend more time caring for patients rather than performing repetitive fabrication tasks. The need for more efficient workflows is becoming increasingly important because the industry faces a shortage of certified prosthetists and orthotists while patient volumes continue to grow. Embla Medical can use the digital and fabrication capabilities developed within its own ForMotion clinics and offer similar services to independent clinics that purchase its products. This helps the company support customers rather than merely sell components to them and may deepen long term relationships with clinicians. Embla Medical’s competitive moat is primarily built on its strong market position in prosthetics, technological expertise, broad product portfolio, extensive intellectual property, clinical relationships, reimbursement capabilities, and growing integration across products and patient care. Its position as the second largest company in the global prosthetics product market gives it meaningful scale in a specialized industry. Developing advanced prosthetic and neuro orthotic products requires expertise in biomechanics, materials science, electronics, software, clinical care, and medical device regulation. Products must be safe, durable, comfortable, and capable of performing consistently in a wide range of real world conditions. A failure can have serious consequences for the user, which makes clinicians and patients cautious about adopting products from unknown suppliers. Embla Medical’s long history and the reputation of the Össur brand provide reassurance that its products have been tested, supported, and used by patients and clinicians around the world. This trust is difficult for a new competitor to build quickly. The company’s scale also allows it to invest consistently in research, product development, clinical documentation, regulatory approvals, manufacturing, sales support, and clinician education. Smaller competitors may be able to develop an individual component, but it is more difficult for them to match Embla Medical’s broad product range, international distribution, regulatory experience, and ability to support products across many countries. Embla Medical introduces new products regularly and uses its relationships with clinicians and patients to identify unmet needs and improve its solutions. Its innovation capabilities are protected by a substantial intellectual property portfolio that consisted of approximately 2.200 patents and patent applications, 820 trademarks, and 560 domain registrations at the end of 2025. Patents can prevent competitors from directly copying particular product designs, control systems, materials, and manufacturing methods, while trademarks protect the company’s brands and product names. However, the deeper advantage is the accumulated expertise developed through decades of research, clinical collaboration, product testing, and experience with thousands of patients. This practical knowledge is embedded in the company’s engineers, clinicians, manufacturing systems, software, product designs, and relationships and cannot easily be reproduced simply by avoiding an individual patent. Another important part of the moat is the close relationship between Embla Medical and the clinicians who prescribe, select, fit, and maintain its products. In prosthetics and orthotics, the end user rarely chooses a product without professional guidance. Certified clinicians assess the patient’s condition and determine which components and technologies are suitable. Clinicians become familiar with specific product systems, fitting methods, software platforms, and suppliers, and they may spend significant time learning how to configure advanced knees, feet, and orthotic joints. Once a clinician has confidence in a product and understands how to fit and support it, there is an incentive to continue using the same supplier. Switching to another manufacturer may require new training, unfamiliar software, changes to fabrication processes, and greater uncertainty about patient outcomes. These factors create switching costs and strengthen established relationships. Embla Medical supports clinicians through education, technical assistance, digital tools, fabrication services, and a broad range of compatible products, making the relationship more valuable than a simple purchase from a component supplier. The breadth of the company’s portfolio reinforces this advantage. A clinic can purchase mechanical and bionic products for different activity levels, components for both lower and upper limbs, liners, materials, neuro orthotic joints, braces, fabrication equipment, and customized services from the same group. This reduces complexity for clinics and allows Embla Medical to serve a larger share of their needs. The company’s growing focus on complete solutions may further strengthen customer relationships because it can provide several of the components, technologies, and services required to create a finished mobility solution. Embla Medical’s Patient Care business also contributes to its competitive position. Owning clinics provides direct contact with patients and clinicians and gives the company insight into how products perform, where clinical workflows are inefficient, and which needs are not being met. These insights can guide product development and help the company design solutions that are easier to fit and more useful in practice. The clinics also provide an internal environment in which new digital fabrication processes, scanning technologies, and products can be tested before being offered more widely. This creates a feedback loop between product development and patient care. Better products and workflows can improve the performance of the clinics, while experience from the clinics can help Embla Medical develop better products and services for both its own facilities and independent providers. Reimbursement expertise represents another barrier to entry. Around 90% of Embla Medical’s products and services are reimbursed, and obtaining reimbursement for advanced medical technology can require clinical studies, health economic evidence, regulatory approval, and discussions with insurers and public healthcare systems. Reimbursement systems differ significantly between countries and may classify patients according to their mobility level, medical condition, and expected benefit from a product. Embla Medical’s international experience helps it understand these systems and support the introduction of new technologies into coverage. Once a product is accepted for reimbursement and incorporated into clinical practice, demand can become relatively stable because the patient does not bear the full cost. Reimbursement also supports the adoption of premium products when the technology can demonstrate better mobility, safety, independence, or health outcomes. he recurring nature of patient needs also strengthens the business. People with limb loss or chronic neurological conditions often require mobility solutions throughout their lives. Prosthetic components, sockets, liners, braces, and orthotic devices wear out, need maintenance, or must be replaced as the patient’s body and needs change. Patients may also upgrade to more advanced products as their activity level changes or new technology becomes available. This creates long term relationships between patients, clinics, and suppliers and provides recurring demand that is less sensitive to short term economic conditions than many consumer markets. However, Embla Medical’s moat is stronger in premium prosthetics and neuro orthotics than in basic bracing products. Some Bracing & Supports categories are less technically differentiated, face more competitors, and experience greater price pressure. Patient Care is also more fragmented and labor intensive, and reimbursement increases do not always fully compensate clinics for rising wages and other costs. Embla Medical’s strongest competitive position therefore lies in areas where advanced technology, clinical outcomes, intellectual property, professional training, and reimbursement capabilities matter most.  Overall, Embla Medical has built an attractive position in a specialized healthcare industry by combining trusted brands, a leading prosthetics franchise, advanced product development, protected technology, close clinical relationships, broad distribution, reimbursement expertise, and direct experience in patient care. These strengths allow the company to serve a wide range of mobility needs while benefiting from recurring demand and long term healthcare trends.

Management

Sveinn Sölvason serves as President and CEO of Embla Medical, a role he assumed in 2022 after previously serving as the company’s Chief Financial Officer for almost a decade. Having worked at Embla Medical since 2009, Sveinn Sölvason brings extensive knowledge of the company, its financial structure, international operations, and long term development. His appointment provided continuity at a time when Embla Medical was evolving from a company primarily associated with the Össur brand into a broader provider of products and patient care services across the global orthotic and prosthetic industry. Before becoming President and CEO, Sveinn Sölvason served as Chief Financial Officer for almost ten years. In that role, Sveinn Sölvason was closely involved in financial planning, capital allocation, acquisitions, investor relations, and the international expansion of the company. The experience gave Sveinn Sölvason a detailed understanding of both the financial and operational sides of Embla Medical before taking responsibility for the entire organization. Sveinn Sölvason first joined the company in 2009 and initially worked within Corporate Development and Treasury, where Sveinn Sölvason gained experience in areas such as acquisitions, financing, and strategic development. Prior to joining Embla Medical, Sveinn Sölvason worked at Marel, Kaupthing Bank, Goldman Sachs, and HSH Nordbank. These roles provided Sveinn Sölvason with experience across industrial companies, banking, corporate finance, and international capital markets. Sveinn Sölvason holds a master’s degree in Finance and Accounting and a bachelor’s degree in International Business, both from Copenhagen Business School. Sveinn Sölvason also serves as a board member of the Icelandic American Chamber of Commerce. Since becoming President and CEO, Sveinn Sölvason has overseen the continued transformation of Embla Medical from a product focused medical technology company into a more broadly integrated mobility solutions provider. This development includes strengthening the company’s position in prosthetics, expanding its presence in neuro orthotics, growing its ForMotion patient care network, and investing in services that support clinicians throughout the process of fitting and manufacturing customized mobility solutions. The change of the parent company’s name from Össur to Embla Medical also took place under the leadership of Sveinn Sölvason and reflected the company’s development into a group with several brands and a broader range of products and services. A central priority under Sveinn Sölvason has been the execution of Embla Medical’s Growth’27 strategy. The strategy focuses on reaching more patients through product innovation, geographical expansion, improved operational execution, and selective acquisitions. Embla Medical has continued to introduce new prosthetic and neuro orthotic products while expanding brands such as Fior & Gentz into additional markets. The company has also invested in digital scanning, fabrication services, direct socket technology, and 3D printing to simplify the production of customized mobility solutions and help clinicians serve a growing number of patients more efficiently. Sveinn Sölvason has also supported the expansion of Embla Medical’s product offering through acquisitions. One important transaction was the acquisition of a majority interest in Streifeneder ortho.production in 2025. The acquisition added orthopaedic materials, equipment, and fabrication solutions and helped position Embla Medical as a more complete supplier to orthotic and prosthetic clinics. According to Sveinn Sölvason, the transaction strengthened the company’s presence in important markets and improved its ability to support clinicians, customers, and patients, particularly in healthcare markets where access to advanced mobility solutions remains less developed. Innovation remains an important part of the strategy led by Sveinn Sölvason. Embla Medical has continued to launch new solutions across the Össur, College Park, and Fior & Gentz brands, including advanced bionic knees, microprocessor controlled feet, and neuro orthotic joints. Sveinn Sölvason has emphasized that innovation must create measurable value for both patients and healthcare systems. This requires Embla Medical not only to develop technically advanced products but also to provide clinical evidence, demonstrate improved patient outcomes, and support the inclusion of new technologies within reimbursement systems. The financial background of Sveinn Sölvason appears to influence a leadership approach that combines growth investments with an emphasis on profitability, operational efficiency, and cash flow. In 2025, Embla Medical delivered organic sales growth of 6% and an EBITDA margin of 20%, supported by strong performance in Prosthetics & Neuro Orthotics. Sveinn Sölvason highlighted effective cost control and operational execution as important contributors to the result. For 2026, Embla Medical guided for organic growth of between 5% and 8% and an EBITDA margin between 20% and 22%, showing that the company intends to grow while maintaining financial discipline. This balance is important because Embla Medical operates across businesses with different growth rates and profitability profiles. Prosthetics & Neuro Orthotics is the company’s strongest growth engine, while Patient Care is more labor intensive and Bracing & Supports operates in a more mature and competitive market. Sveinn Sölvason therefore faces the challenge of allocating resources toward the most attractive opportunities while improving performance in the slower growing parts of the group. Recent results indicate that the company remains particularly focused on premium prosthetics and neuro orthotics, where innovation, clinical differentiation, and new product introductions can support stronger growth and a more favorable product mix. Sveinn Sölvason has also emphasized the importance of reaching more patients rather than focusing exclusively on selling additional products. This patient focused approach is reflected in Embla Medical’s ownership of ForMotion clinics and its efforts to improve the entire process through which mobility solutions are prescribed, manufactured, fitted, and maintained. By combining proprietary products with clinical services and digital fabrication capabilities, Embla Medical aims to become more valuable to patients, independent clinics, healthcare professionals, and payers. The long tenure of Sveinn Sölvason within Embla Medical is a meaningful advantage. Sveinn Sölvason has worked within the organization for more than fifteen years and has experience from corporate development, treasury, finance, acquisitions, and executive leadership. This means Sveinn Sölvason understands the company’s culture, products, markets, and financial characteristics while also having participated in much of its international development. The progression of Sveinn Sölvason from internal financial and strategic roles to Chief Financial Officer and ultimately President and CEO suggests that the board valued continuity and company specific knowledge when selecting its leader. Given the extensive experience of Sveinn Sölvason within Embla Medical, the financial discipline developed during almost a decade as Chief Financial Officer, and the focus on innovation, acquisitions, and patient focused mobility solutions, Sveinn Sölvason appears well suited to lead the company through its next phase of growth. The strategy under Sveinn Sölvason builds on Embla Medical’s established strengths in prosthetics while expanding into faster growing areas such as neuro orthotics, digital fabrication, complete clinic solutions, and patient care. The ability of Sveinn Sölvason to maintain strong product innovation, allocate capital sensibly, and improve performance across the broader group will be important in determining whether Embla Medical can convert its attractive market position into sustainable long term value creation.

The Numbers

The first number we will look into is the return on invested capital, also known as ROIC. We want to see a 10-year history, with all numbers exceeding 10% in each year. Unfortunately, Embla Medical falls well short of this target. Over the past decade, ROIC has remained below 10% every year, ranging from 4,1% to 9,7%. The decline in 2020 and the relatively modest recovery since then suggest that the company has not yet reached the level of profitability and capital efficiency that I typically look for in an ideal long term investment. Several characteristics of Embla Medical's business help explain why ROIC has historically been lower than that of many high quality compounders. First, the company operates in the medical technology industry, where developing innovative prosthetic and orthotic solutions requires significant ongoing investment in research and development, regulatory approvals, clinical studies, manufacturing, and specialized sales organizations. Unlike software or branded consumer products, these investments are substantial and increase the amount of capital required to grow the business. Second, Embla Medical's products are highly customized. While the company manufactures many standardized components, every prosthetic or neuro orthotic solution ultimately needs to be fitted and customized to the individual patient by trained clinicians. This requires a large clinical support organization, technical specialists, digital fabrication capabilities, and investments in technologies such as scanning, direct socket production, and 3D printing. These investments strengthen the company's competitive position but also increase the capital employed in the business. Third, Embla Medical owns and operates its own Patient Care business through the ForMotion network. While these clinics provide valuable relationships with patients, clinicians, and payers, they are considerably more capital and labor intensive than simply selling products through independent distributors. Running clinics requires investments in facilities, specialized equipment, and highly trained healthcare professionals. These additional investments naturally reduce returns on invested capital compared to a business that only develops and sells medical products. The acquisitions completed over the years have also affected ROIC. Embla Medical has expanded through acquisitions such as College Park, Fior & Gentz, and most recently Streifeneder ortho.production. These acquisitions have strengthened the company's technology, broadened its product portfolio, and expanded the markets it serves. However, acquiring companies also requires significant investment, and it often takes time before the acquired businesses contribute enough earnings to fully justify the purchase price. As a result, acquisitions can temporarily reduce returns on invested capital before their full benefits are realized. The sharp decline in ROIC during 2020 was largely driven by the COVID 19 pandemic. Elective surgeries were postponed, many clinics temporarily closed or operated at reduced capacity, and patient visits declined significantly. Since many of Embla Medical's costs are relatively fixed, lower sales had a disproportionate impact on operating profits, causing ROIC to fall to just above 4%. While profitability has improved since then, ROIC has only gradually recovered to around 7%, reflecting both the normalization of earnings and continued investments in the business. Looking ahead, I believe ROIC has the potential to improve, although it may remain below the levels achieved by many of the highest quality compounders. One reason is that Prosthetics & Neuro Orthotics, the company's highest margin and fastest growing segment, is becoming an increasingly important part of the business. Premium bionic knees, microprocessor controlled feet, and neuro orthotic products generally carry higher margins than traditional braces or clinical services, and continued growth in these categories should gradually improve the overall profitability of the group. Embla Medical is also investing heavily in digital workflows, scanning technology, centralized fabrication, direct socket solutions, and 3D printing. These initiatives are designed to make clinicians more productive while reducing the time and cost required to manufacture customized mobility solutions. If these technologies are adopted more broadly, they could improve operating margins without requiring a proportional increase in invested capital, supporting higher ROIC over time. In addition, management's Growth'27 strategy aims to increase operational efficiency, improve the product mix, and expand into faster growing markets such as neuro orthotics. As newer products mature and recently acquired businesses become more integrated, profitability could improve further. However, Embla Medical is unlikely to become an asset light business. The combination of manufacturing, clinical support, patient care clinics, and ongoing investment in innovation means the company will likely continue requiring significant capital to support its growth. As a result, while ROIC should gradually improve over time, it is more realistic to expect returns in the high single digits or low double digits than exceptionally high levels.

The next numbers are the book value + dividend. In my old format this was known as the equity growth rate. It was the most important of the four growth rates I used to use in my analyses, which is why I will continue to use it moving forward. As you are used to see the numbers in percentage, I have decided to share both the numbers and the percentage growth year over year. To put it simply, equity is the part of the company that belongs to its shareholders – like the portion of a house you truly own after paying off part of the mortgage. Growing equity over time means the company is becoming more valuable for its owners. So, when we track book value plus dividends, we’re essentially looking at how much value is being built for shareholders year after year. Embla Medical has generally delivered solid growth in equity over the past decade. Apart from declines in 2017 and 2020, equity has increased every year, with particularly strong growth in 2021 and 2024. This suggests that the company has consistently created value for shareholders by generating profits and reinvesting a meaningful portion of those earnings back into the business. The primary driver of equity growth has been Embla Medical's consistent profitability. As the company earns profits and retains part of those earnings instead of distributing all of them to shareholders, equity gradually increases over time. This has been supported by steady demand for the company's mobility solutions and by long term structural trends such as aging populations, increasing rates of diabetes and osteoarthritis, and improved access to advanced prosthetic and orthotic treatments. These factors have allowed Embla Medical to expand its business while steadily building shareholder value. Another contributor has been the company's disciplined acquisition strategy. Over the years, Embla Medical has acquired businesses such as College Park, Fior & Gentz, and Streifeneder ortho.production, expanding its product portfolio, technological capabilities, and geographic reach. While acquisitions require significant investment, they have also helped increase the company's earnings over time, which has supported the long term growth in equity. The declines in equity during 2017 and 2020 were primarily driven by temporary factors rather than a deterioration of the underlying business. The decline in 2020 coincided with the COVID 19 pandemic, when postponed elective procedures and reduced patient visits affected profitability. Lower earnings meant that less value was added to equity during the year. As demand recovered, equity growth rebounded strongly, increasing by 16,5% in 2021. The modest increase of 1,3% in 2025 reflects a year in which equity had already reached a significantly higher level following several years of strong growth, while the company also continued investing in acquisitions and strategic initiatives to support future growth. Unlike many companies that prioritize returning large amounts of capital to shareholders through share repurchases, Embla Medical has generally retained a larger portion of its earnings to fund acquisitions, product development, manufacturing capabilities, digital technologies, and the expansion of its Patient Care business. This approach has allowed the company to steadily increase the value of the business while investing in future growth opportunities. Looking ahead, I believe Embla Medical should be able to continue growing equity over time. Demand for mobility solutions is expected to benefit from favorable demographic trends, and management's Growth'27 strategy focuses on expanding the company's product portfolio, improving operational efficiency, and increasing its presence in attractive markets such as neuro orthotics. As long as the company remains profitable and continues allocating capital prudently, equity should continue to grow. That said, the pace of growth will likely vary from year to year depending on profitability, acquisitions, and the timing of investments. Overall, Embla Medical's track record of steadily building equity provides confidence that the company can continue creating value for shareholders over the long term.

Finally, we will analyze the free cash flow. Free cash flow, in short, refers to the cash that a company generates after covering its operating expenses and capital expenditures. I use levered free cash flow margin because I believe that margins provide a better understanding of the numbers. Free cash flow yield refers to the amount of free cash flow per share that a company is expected to generate in relation to its market value per share. Embla Medical has historically generated solid and relatively consistent free cash flow despite operating in a capital intensive medical technology industry. While free cash flow has fluctuated from year to year, the overall trend has been positive, reaching its highest level ever in 2025. The company's levered free cash flow margin has also remained healthy, generally ranging between 8% and 12%, demonstrating its ability to convert a meaningful portion of revenue into cash. One of the primary reasons Embla Medical generates solid free cash flow is its consistent operating profitability. The company serves markets with recurring demand, as many patients require mobility solutions throughout their lives and regularly replace or upgrade prosthetic components, braces, and orthotic devices. Combined with favorable demographic trends such as aging populations, increasing rates of diabetes, osteoarthritis, and neurological disorders, this provides a stable foundation for cash generation. Because around 90% of the company's products and services are reimbursed by public healthcare systems or private insurers, demand is also less dependent on patients' personal finances than in many other industries. Another important factor is Embla Medical's disciplined investment approach. Although the company continuously invests in research and development, manufacturing, digital technologies, and patient care facilities, these investments have generally remained at manageable levels relative to the cash generated by the business. Capital expenditures returned to a more normal level in 2025 after elevated spending in 2024 related to the expansion of manufacturing facilities. As these large investment projects were completed, a greater share of operating cash flow was converted into free cash flow. This normalization of capital expenditures was one of the main reasons free cash flow reached its highest level ever in 2025. In addition to lower capital expenditures, the improvement was supported by strong operating performance as Embla Medical continued to grow revenue and improve profitability, particularly within Prosthetics & Neuro Orthotics, its fastest growing and highest margin business segment. Free cash flow can still fluctuate from year to year. In 2022, for example, free cash flow declined despite continued growth in the business. This illustrates that annual cash generation can be affected by the timing of investments and other short term factors rather than changes in the underlying quality of the business. Over longer periods, however, Embla Medical has demonstrated an ability to consistently generate healthy amounts of cash while continuing to invest for future growth. Looking ahead, I believe Embla Medical is well positioned to continue growing its free cash flow. Demand for its products is supported by attractive long term demographic trends, while management's Growth'27 strategy focuses on expanding the company's premium prosthetics and neuro orthotics businesses, improving operational efficiency, and increasing the use of digital technologies such as scanning, direct socket solutions, and 3D printing. These initiatives should help improve productivity and profitability over time. Management has also indicated that capital expenditures are expected to remain around their more normalized level following the completion of recent facility expansion projects. This should allow a larger share of future operating profits to be converted into free cash flow, although cash generation will naturally vary depending on the timing of acquisitions and strategic investments. Embla Medical has a disciplined capital allocation policy that determines how it uses its free cash flow. The company's first priority is to invest in organic growth opportunities, including product innovation, manufacturing capabilities, digital technologies, and the expansion of its Patient Care business. It also uses free cash flow to fund acquisitions that strengthen its technology portfolio, expand its geographic presence, or broaden its offering to orthotic and prosthetic clinics. Management aims to maintain a healthy balance sheet while pursuing these growth opportunities. Once these priorities have been addressed, excess capital is returned to shareholders through share repurchases. Embla Medical discontinued its dividend in 2022 and instead adopted share buybacks as its preferred method of returning capital. During 2025, the company completed a share buyback program and initiated a new one at the beginning of 2026. This approach gives management greater flexibility because buybacks can be adjusted depending on acquisition opportunities, investment needs, and market conditions. The free cash flow yield suggests that Embla Medical is trading at one of its most attractive valuations in more than a decade. However, we will revisit valuation later in the analysis.

Debt

Another important aspect to consider is debt. It is crucial to evaluate whether a company has a manageable debt level that can be repaid within three years, which is determined by dividing total long-term debt by earnings. Analyzing Embla Medical’s financials, we find that the company has 3,5 years of earnings in debt. This is slightly above my preferred threshold. However, I do not consider the debt level to be a major concern. Embla Medical generates consistent free cash flow, operates in markets with stable demand, and has a history of disciplined capital allocation. Management also targets a conservative debt level and remains comfortably within its own target range. As long as the company continues generating healthy cash flow and allocating capital prudently, I believe the current debt level is manageable.

Support the Blog

I want to keep the blog free and accessible for everyone. If you enjoy the content and would like to support it, you can buy me a cup of coffee through PayPal. Every little bit helps and is truly appreciated!

Risks

Macroeconomic factors are a risk for Embla Medical because, although demand for many of the company's products is supported by long term healthcare needs, the business is not completely insulated from broader economic conditions. Embla Medical operates in more than 40 countries and generates revenue across the Americas, Europe, and Asia Pacific. Changes in economic growth, inflation, interest rates, labor costs, geopolitical developments, and global trade conditions can therefore influence both the company's financial performance and its ability to execute its long term strategy. One important risk is inflation. Embla Medical relies on a global manufacturing and distribution network, and higher costs for raw materials, components, energy, transportation, and wages can increase its operating expenses. While the company can sometimes offset these higher costs through price increases or productivity improvements, there is often a delay before higher costs can be reflected in prices. This can temporarily pressure profit margins and reduce cash flow. Higher interest rates can also affect the business. Embla Medical has historically used debt to finance acquisitions and support its growth strategy. Although the company maintains what it considers to be a prudent level of debt, higher interest rates increase borrowing costs and can make future acquisitions more expensive to finance. This could reduce financial flexibility or slow the pace of acquisition driven growth if financing conditions become less favorable. Economic uncertainty can also influence customers' investment decisions. While patients with chronic mobility needs continue to require treatment, orthotic and prosthetic clinics may delay investments in new equipment, digital technologies, or facility upgrades during periods of economic uncertainty. Embla Medical has noted that many customers remain focused on controlling costs and improving productivity, which is one reason the company continues investing in technologies such as digital scanning, centralized fabrication, and 3D printing that help clinics operate more efficiently. However, if economic conditions remain challenging for an extended period, some customers may postpone investments or purchases, which could temporarily reduce demand for certain products and services. Labor shortages also represent a broader macroeconomic challenge. The orthotic and prosthetic industry faces an ongoing shortage of certified prosthetists and orthotists, while demand for mobility solutions continues to grow. A limited supply of qualified clinicians can constrain the number of patients that clinics are able to treat, potentially slowing industry growth even when underlying patient demand remains strong. Embla Medical is investing in digital workflows and fabrication technologies to improve clinician productivity, but these solutions are unlikely to eliminate the shortage entirely. Geopolitical developments have also become an increasingly important risk. Embla Medical manufactures products in several countries and serves customers around the world through a global supply chain. As a result, trade restrictions, tariffs, sanctions, and other geopolitical developments can increase costs, disrupt the supply of components, create additional compliance requirements, or make it more difficult to serve certain markets efficiently. Management has already stated that tariffs increased costs during 2025 and expects the impact to be somewhat higher in 2026 if current tariff levels remain in place. While the financial impact has so far been manageable, it illustrates how changes in global trade policy can affect profitability even when demand for the company's products remains strong.

Competition is a risk for Embla Medical because the markets in which it operates are competitive and, in many cases, highly fragmented. While Embla Medical holds leading positions in several niche markets, it competes against both large global medical technology companies and numerous regional and local manufacturers. The company must continuously innovate, maintain strong relationships with clinicians, and demonstrate superior patient outcomes to defend and expand its market position. If competitors introduce better products, lower prices, or more efficient solutions, Embla Medical could lose market share or face pressure on profitability. Competition varies across the company's business segments. In Prosthetics, Embla Medical is the second largest company globally with an estimated market share of around 25%, but it competes with a number of well established companies that continue to invest heavily in research and development. Innovation is particularly important in this market because clinicians and patients increasingly demand products that provide greater comfort, improved mobility, and more natural movement. Competitors are continuously developing new microprocessor controlled knees, bionic feet, upper limb prostheses, and digital technologies that seek to improve patient outcomes. If a competitor develops a superior product or brings new technologies to market more quickly, Embla Medical could lose market share in one of its most important and profitable businesses. Competition is even more intense in Bracing & Supports. Management has highlighted that the U.S. bracing market remains highly competitive, with pricing pressure in several important product categories. Many braces are less technologically differentiated than advanced prosthetic products, making it easier for competitors to compete on price. As a result, Embla Medical may face pressure to reduce prices in order to protect market share, which can weigh on margins even if sales volumes remain stable. The Patient Care market is also highly fragmented. Although Embla Medical is among the largest providers globally through its ForMotion network, its market share is estimated at only around 2%, leaving thousands of independent clinics and numerous regional providers competing for patients. Competition for skilled clinicians is particularly important because orthotic and prosthetic care depends heavily on the expertise of certified prosthetists and orthotists. A shortage of qualified professionals can make it more difficult to recruit and retain employees, while competitors may attempt to attract experienced clinicians who have established relationships with patients and referring physicians. Another competitive challenge comes from new entrants and technological innovation. Advances in digital scanning, computer aided design, 3D printing, robotics, artificial intelligence, and manufacturing technologies lower some of the barriers to developing customized mobility solutions. While Embla Medical has invested heavily in these technologies and remains at the forefront of many of these developments, competitors are making similar investments. If another company develops more effective digital workflows or more advanced mobility solutions, Embla Medical may need to increase research and development spending or lower prices to remain competitive.

Reimbursement and healthcare policy are risks for Embla Medical because the company relies heavily on third party payers to fund its products and services. Approximately 90% of Embla Medical's products and services are reimbursed by government healthcare programs or private health insurance companies. While this provides a relatively stable source of demand, it also means that the company depends on reimbursement systems that it cannot directly control. Changes in healthcare policy, reimbursement rules, or insurance coverage can therefore have a significant impact on sales and profitability. Healthcare systems and insurance companies continually look for ways to control rising healthcare costs. They may reduce reimbursement levels, introduce stricter approval requirements, increase documentation requirements, or limit coverage for certain products or patient groups. If reimbursement becomes less favorable, healthcare providers may be less willing to prescribe premium mobility solutions, while patients may choose less advanced alternatives or delay treatment altogether. This could reduce demand for some of Embla Medical's higher value products and put pressure on both revenue and margins. Reimbursement decisions are particularly important for Embla Medical because many of its products are among the most technologically advanced and expensive mobility solutions available. Products such as microprocessor controlled knees, bionic prosthetic feet, and advanced neuro orthotics can provide significant improvements in mobility and quality of life, but they also carry higher prices than more traditional solutions. The commercial success of these products therefore depends not only on demonstrating superior clinical outcomes but also on convincing healthcare systems and insurance providers that the additional benefits justify the higher cost. If reimbursement authorities become more restrictive, adoption of these advanced technologies could slow. The reimbursement landscape also differs significantly from country to country. Embla Medical operates in more than 40 countries, each with its own healthcare system, funding model, and reimbursement rules. As a result, the company must continuously adapt to changing regulations, documentation requirements, and payment systems across multiple jurisdictions. Changes in government healthcare budgets, insurance policies, or reimbursement criteria in one or more major markets could affect the company's financial performance even if underlying patient demand remains strong. Another risk is that reimbursement reviews may become more stringent over time. Healthcare payers increasingly require evidence that new products improve patient outcomes while also providing value for money. Embla Medical therefore invests heavily in clinical studies and health economic research to demonstrate the benefits of its products. While these investments strengthen the company's competitive position, there is no guarantee that new products will receive the reimbursement levels management expects or that existing reimbursement policies will remain unchanged. Embla Medical's Patient Care business adds another layer of reimbursement risk. In addition to selling products, the company operates its own network of orthotic and prosthetic clinics through the ForMotion brand. These clinics depend on reimbursement not only for the products they provide but also for the clinical services involved in assessing, fitting, adjusting, and maintaining mobility solutions. Changes in reimbursement for either products or clinical services could therefore affect both parts of the business simultaneously.

Reasons to invest

Structural global trends are a reason to invest in Embla Medical because the company operates in markets that benefit from several long term demographic, healthcare, and technological trends. Unlike many businesses that depend on short term economic cycles or changing consumer preferences, demand for Embla Medical's mobility solutions is supported by factors that are expected to develop over decades. These trends include aging populations, rising rates of chronic diseases, improving access to healthcare, increasing adoption of advanced mobility technologies, digitalization, and growing demand for cost effective healthcare solutions. Together, these trends create a favorable environment for long term growth. One of the most important drivers is the aging of the global population. As people live longer, the number of individuals suffering from mobility limiting conditions continues to increase. Older adults are more likely to develop vascular disease, diabetes, osteoarthritis, and other conditions that can lead to limb loss or reduced mobility. At the same time, today's older population is generally more active than previous generations and has higher expectations for maintaining independence and quality of life. This increases demand not only for prosthetic and orthotic solutions but also for more advanced products that help people remain active for longer. The increasing prevalence of chronic diseases also supports long term demand. Vascular disease, particularly complications related to diabetes, remains the leading cause of lower limb amputations worldwide. As the number of people living with diabetes and vascular disease continues to rise, so does the number of patients requiring prosthetic care. Many of these patients become lifelong users of mobility solutions that require regular maintenance, replacement, and upgrades. This creates recurring demand throughout the patient's lifetime rather than a single one time sale. The same applies to many neurological conditions such as stroke, multiple sclerosis, cerebral palsy, and spinal cord injuries, which continue to support growing demand for neuro orthotic solutions. Another important opportunity comes from improving healthcare access in emerging markets. Approximately 80% of new amputees globally live in emerging economies, yet these markets currently account for only a small share of Embla Medical's revenue. In many of these countries, access to prosthetic care remains limited because of inadequate healthcare infrastructure, limited reimbursement, and a shortage of trained clinicians. As healthcare systems continue to develop, disposable incomes rise, and insurance coverage expands, significantly more patients are expected to gain access to advanced mobility solutions. Embla Medical has identified this as one of its largest long term growth opportunities and is gradually expanding its presence in these markets. India is one example, where the company has begun establishing patient care operations to improve access to prosthetic treatment while addressing barriers such as affordability, awareness, and clinical capacity. The company also benefits from ongoing improvements in medical technology. Prosthetic and neuro orthotic solutions have become increasingly sophisticated through advances in microprocessors, sensors, robotics, software, and artificial intelligence. These innovations allow patients to walk more naturally, improve balance, climb stairs more easily, and participate in a wider range of daily activities. As these technologies continue to improve and become more widely accepted, more patients are likely to choose advanced mobility solutions over traditional alternatives. Embla Medical is well positioned to benefit from this trend given its strong position in premium prosthetics and neuro orthotics and its continuous investment in product development. Digitalization represents another structural growth driver. Embla Medical is increasingly integrating digital scanning, computer aided design, centralized fabrication, direct socket technology, and 3D printing into the process of designing and fitting mobility solutions. These technologies improve efficiency, reduce production times, increase consistency, and allow clinicians to spend more time treating patients rather than manually manufacturing customized components. This is particularly important because the orthotic and prosthetic industry faces an ongoing shortage of certified prosthetists and orthotists. By improving productivity through digital workflows, Embla Medical can help clinics serve more patients without requiring a proportional increase in clinical staff.

Innovation is a reason to invest in Embla Medical because innovation has been at the core of the company's strategy since its founding more than 50 years ago. The company develops advanced mobility solutions that improve the lives of people living with limb loss, neurological disorders, osteoarthritis, and other mobility limiting conditions. Unlike many medical technology companies that primarily compete on price, Embla Medical focuses on developing products and technologies that improve patient outcomes, increase mobility, simplify clinical workflows, and strengthen its long term competitive position. Management considers innovation to be one of the company's most important growth drivers and has invested nearly USD 200 million in research and development over the past five years. As the business continues to grow, management expects research and development spending to increase further while maintaining a focus on generating attractive long term returns. Embla Medical has demonstrated a strong track record of consistently bringing new products to market. During 2025 alone, the company introduced several important innovations, including the Navii bionic knee, the Icon microprocessor controlled knee through College Park, the Odyssey iQ bionic foot, the Pro Flex LP Junior prosthetic foot for children, improvements to the Power Knee, and the AeroFit liner that significantly reduces heat and moisture inside a prosthetic socket through proprietary 3D printed silicone technology. Management has repeatedly highlighted that recently launched products have been an important contributor to the company's organic growth, demonstrating that innovation is translating into commercial success rather than remaining limited to the research laboratory. Innovation at Embla Medical is not simply about launching new products. The company continuously upgrades existing products to improve mobility, comfort, durability, and ease of use. Recent improvements to the Power Knee introduced a more advanced walking algorithm, making movement more natural while increasing user confidence and independence. Other innovations have focused on making products more durable, waterproof, and comfortable, allowing patients to participate more fully in everyday activities. These incremental improvements strengthen customer loyalty while encouraging existing users to upgrade to newer products over time. One of the most attractive aspects of Embla Medical's innovation strategy is its focus on increasing the adoption of premium mobility solutions. Many patients still use mechanical prosthetic devices even though more advanced bionic products can provide better mobility and quality of life. As technology continues to improve and healthcare systems increasingly recognize the long term benefits of these solutions, more patients are expected to upgrade to higher value products. This is particularly attractive because premium prosthetic solutions generally generate higher margins while also delivering better outcomes for patients. Management has specifically identified increased bionic penetration and functional trade up as key drivers of future growth. The company also has an attractive innovation pipeline that extends well beyond its current products. One of the most anticipated projects is a dedicated microprocessor controlled knee designed for lower activity users, often referred to as K2 patients. Existing bionic knees have primarily been developed for more active amputees, leaving a significant portion of the market underserved. Management expects this product to launch in 2027 and believes it will complement the existing portfolio of Navii, Rheo Knee, and Icon products while expanding the addressable market. The company is also developing the next generation of multi articulating prosthetic hands and advancing bionic ankle and knee solutions within its Fior & Gentz neuro orthotics business. Another encouraging aspect is that management closely measures whether innovation creates commercial value. The company tracks what it calls R&D impact, which measures the proportion of annual sales generated by products launched during the previous five years. This figure has increased from approximately 15% to more than 25% in recent years, meaning that more than one quarter of the company's revenue now comes from relatively new products. This demonstrates that Embla Medical is not simply investing heavily in research and development but is successfully converting those investments into products that customers are willing to purchase. Innovation also helps strengthen Embla Medical's competitive position. The company holds one of the largest intellectual property portfolios in the orthopedic industry and combines expertise in biomechanics, robotics, sensors, artificial intelligence, software, materials science, and clinical care. Management has even highlighted that this knowledge could create future opportunities beyond traditional prosthetics, including potential collaborations related to humanoid robotics, although this remains a longer term possibility rather than part of the current investment case.

The global clinic network is a reason to invest in Embla Medical because it gives the company direct access to patients and allows it to participate in a larger part of the orthotic and prosthetic value chain. Through the ForMotion brand, Embla Medical operates approximately 200 clinics across 12 countries. These clinics assess patients, recommend suitable mobility solutions, customize and fit prosthetic and orthotic devices, and provide ongoing adjustments and support. This means Embla Medical is not only a manufacturer selling products to healthcare providers. It also participates directly in delivering mobility solutions to the people who use them. This is particularly valuable because prosthetic and orthotic care requires much more than simply purchasing a product. Many devices must be customized to the individual patient, and the quality of the result depends heavily on the skill of the clinician who assesses, fits, and adjusts the solution. Patients may need several visits before the device functions properly, followed by regular maintenance, modifications, and replacement over time. By operating its own clinics, Embla Medical gains a deeper understanding of patient needs, clinical workflows, and the practical challenges involved in delivering high quality mobility care. The clinic network also provides Embla Medical with recurring revenue. Most patients visiting orthotic and prosthetic clinics live with chronic mobility challenges and require support throughout their lives. Prosthetic sockets, liners, joints, feet, braces, and other components may need to be maintained, adjusted, or replaced as they wear out or as the patient’s body and mobility needs change. Embla Medical estimates that approximately 70% to 80% of revenue within the clinic business is recurring. This makes the business less dependent on constantly finding entirely new customers and creates long lasting relationships between patients, clinicians, and the company. These relationships can be particularly strong because patients often develop a high degree of trust in the clinician responsible for their care. A prosthesis or custom orthotic device can have a significant effect on comfort, independence, and quality of life, and patients may be reluctant to switch provider once they have found a clinician who understands their needs. This creates a relatively sticky business in which satisfied patients are likely to return for future adjustments, replacement products, and ongoing support. The clinic network also creates a valuable feedback loop between Embla Medical’s product development and the people using its products. By working directly with patients and clinicians, Embla Medical can identify problems with comfort, fit, durability, and ease of use and use these insights to improve future products. Its clinics also provide a setting in which new technologies, digital workflows, and fabrication methods can be tested in real clinical situations. This gives Embla Medical knowledge that a manufacturer without direct patient contact may find more difficult to obtain. Embla Medical has built the clinic network through numerous acquisitions over the past decade. Historically, many of the acquired clinics continued operating with their own brands, systems, and ways of working. This meant the company owned a collection of local businesses rather than a fully integrated global network. Over the past 18 months, management has been working to change this by bringing the clinics together under the ForMotion brand and introducing more consistent systems, processes, and performance measurements. The global rollout of the ForMotion brand was completed during the second quarter of 2026, bringing all of the company’s clinics under a single patient focused identity. Management has also been introducing shared systems and more standardized ways of working across the network. These changes are intended to make the business easier to manage, improve consistency between clinics, and allow Embla Medical to benefit more fully from its global scale. A major opportunity lies in improving productivity across the network. The financial performance of each clinic depends largely on how many patients it attracts, how many patients each clinician can treat, and whether the clinic uses its facilities and staff efficiently. Embla Medical is therefore working to improve patient intake, simplify administrative tasks, standardize purchasing, and introduce digital tools that allow clinicians to spend more time treating patients. Digital scanning, centralized fabrication, direct socket technology, and 3D printing can reduce the amount of manual work required to produce customized components and help each clinician serve more people. There is also room to improve margins because Embla Medical has already established much of the central structure required to support the clinic network. Once shared systems, processes, branding, and management structures are in place, additional growth should not require the same increase in costs. Management has indicated that improved sales growth would therefore make a meaningful contribution to profitability. The clinic network also supports Embla Medical’s broader goal of reaching more patients. Globally, only around one in three new amputees receives a prosthetic device, which highlights the significant unmet need for mobility care. By expanding its clinical presence and improving the efficiency of each location, Embla Medical can help more patients gain access to appropriate treatment.

Unlock Exclusive Seeking Alpha Discounts – Level Up Your Investing With Zero Risk

If you’ve been thinking about improving your investing process, this is the easiest way to start. These offers are only available through my links, and the Premium plan even comes with a 100% risk-free 7-day trial. Try everything for a week, and if it’s not for you, just cancel. You lose nothing.

1) Seeking Alpha Premium — Try It Free for 7 Days

Access the tools I personally use every day:

• Earnings transcripts

• Stock screeners

• Deep-dive analysis

• Portfolio tracking

• Market news with context that actually matters

Special Price: $269/year (normally $299) + 7-day free trial (for new users only)

Try Premium Free for 7 Days → HERE

(Explore everything — cancel anytime during the trial and pay $0.)

2) Alpha Picks — Proven Stock Ideas

This stock-picking service has delivered +287% returns vs. the S&P 500’s +77% (July 2022–Nov 2025).Great for investors who want curated, long-term picks backed by data.

Special Price: $449/year (normally $499)

Get Alpha Picks → HERE

(Although Alpha Picks doesn’t offer a free trial, its historical outperformance means the subscription can often pay for itself quickly if results persist. For many investors, the potential return far outweighs the upfront cost).

3) Premium + Alpha Picks Bundle — Best Value

Get both services together and save $159.Perfect if you want both broad tools and high-conviction stock ideas.

Special Price: $639/year (normally $798)

Get the Bundle → HERE

(This bundle doesn’t include a free trial, but it gives you both services at a $159 discount. You get Premium’s in-depth research plus Alpha Picks’ high-performing recommendations, making it the most comprehensive option for serious investors.)

Valuation

Now it is time to calculate the share price. I perform three different calculations that I learned at a Phil Town seminar. If you want to make the calculations yourself for this or other stocks, you can do so through the tools page on my website, where you have access to all three calculators for free.

The first is called the Margin of Safety price, which is calculated based on earnings per share (EPS), estimated future EPS growth, and estimated future price-to-earnings ratio (P/E). The minimum acceptable rate of return is 15%. I chose to use an EPS of 1,24, which is from 2025. I have selected a projected future EPS growth rate of 15%. Finbox expects EPS to grow by 15,8% a year in the next five years, but 15% is the highest I use.  Additionally, I have selected a projected future P/E ratio of 30, which is twice the growth rate. This decision is based on Embla Medical's historically higher price-to-earnings (P/E) ratio. Finally, our minimum acceptable rate of return has already been established at 15%. After performing the calculations, we determined the sticker price (also known as fair value or intrinsic value) to be DKK 37,20. We want to have a margin of safety of 50%, so we will divide it by 2. This means that we want to buy Embla Medical at a price of DKK 18,60 (or lower, obviously) if we use the Margin of Safety price.

The second calculation is known as the Ten Cap price. The rate of return that a company owner (or stockholder) receives on the purchase price of the company essentially represents its return on investment. The minimum annual return should be at least 10%, which I calculate as follows: The operating cash flow last year was 843, and capital expenditures were 140. I attempted to analyze their annual report to calculate the percentage of capital expenditures allocated to maintenance. I couldn't find it, but as a rule of thumb, you can expect that 70% of the capital expenditures will be allocated to maintenance purposes. This means that we will use 98 in our calculations. The tax provision was 154. We have 427,3 outstanding shares. Hence, the calculation will be as follows: (843 – 98 + 154) / 427,3 x 10 = DKK 21,04 in Ten Cap price.

The final calculation is called the Payback Time price. It is a calculation based on the free cash flow per share. With Embla Medical's Free Cash Flow Per Share at DKK 1,64 and a growth rate of 15%, if you want to recoup your investment in 8 years, the Payback Time price is DKK 25,89.

Conclusion

I believe that Embla Medical is an intriguing company with capable management. Its competitive moat is built on its leading position in prosthetics, technological expertise, broad product portfolio, extensive intellectual property, clinical relationships, reimbursement capabilities, and growing integration across products and patient care. Embla Medical's ROIC has remained below 10% throughout the past decade because its business requires substantial investment in innovation, manufacturing, customized solutions, clinics, and acquisitions. ROIC may improve as higher margin prosthetics and neuro orthotics grow and digital tools increase productivity, but returns are likely to remain in the high single digits or low double digits rather than reach exceptionally high levels. Embla Medical has consistently generated solid free cash flow despite operating in a capital intensive industry, reaching a record level in 2025 as capital expenditures normalized and profitability improved. With recurring demand, favorable structural growth drivers, and continued investments in higher margin products and productivity initiatives, I believe the company is well positioned to grow free cash flow over the long term. Macroeconomic factors are a risk for Embla Medical because inflation, higher interest rates, labor shortages, tariffs, and geopolitical disruptions can increase costs, weaken profitability, delay customer investments, and make acquisitions more expensive. Global trade restrictions and supply chain disruptions may also affect the availability of components and the company's ability to serve markets efficiently. Competition is a risk for Embla Medical because it operates in highly competitive and fragmented markets where success depends on continuous innovation, strong clinical relationships, and superior patient outcomes. Increased pricing pressure, particularly in Bracing & Supports, and competitors introducing better technologies or more efficient solutions could reduce market share and pressure profitability. Reimbursement and healthcare policy are risks for Embla Medical because approximately 90% of its products and services rely on reimbursement from government healthcare programs or private insurers. Changes to reimbursement levels, coverage, or healthcare policies could reduce the adoption of the company's premium mobility solutions and negatively affect both revenue and profitability. Structural global trends are a reason to invest in Embla Medical because aging populations, rising rates of chronic diseases, improving healthcare access, and continued advances in mobility technologies are expected to support long term demand for the company's products. These trends, combined with growing adoption of premium mobility solutions and digital workflows, provide a strong foundation for sustainable long term growth. Innovation is a reason to invest in Embla Medical because the company has a long track record of developing advanced mobility solutions that improve patient outcomes while supporting profitable growth. Continued investment in research and development, a strong product pipeline, and increasing adoption of premium bionic solutions should strengthen its competitive position and drive long term growth. The global clinic network is a reason to invest in Embla Medical because it gives the company direct relationships with patients, generates recurring revenue, and provides valuable clinical insights that support product development and innovation. As the ForMotion network becomes more integrated and productive, it also has the potential to improve profitability while helping Embla Medical reach more patients. I believe there are many things to like about Embla Medical, and buying shares at the Ten Cap price of DKK 21 could represent an attractive long term investment.

Follow my investment journey

I hope you enjoyed this analysis. I regularly publish in depth company analyses on InvestSeekers and share updates on the companies I follow.

If you would like to see what I currently invest in, I publicly share my portfolio and any changes I make over time. You can also learn how to follow or copy my portfolio through the investment platform I use.

See my Portfolio and Learn How to Copy it.

Stay updated

If you enjoy my company analyses, you can sign up for my free newsletter to receive my latest analyses, investment ideas, and other updates directly in your inbox. Subscribers may also receive selected content before it is published publicly on InvestSeekers. Simply scroll to the bottom of this page and sign up.

Watch on YouTube

If you prefer a faster and more visual way to understand a company, I also publish videos on YouTube covering Nordic companies that receive relatively little coverage in English. Each video provides an understandable overview of the business, financials, risks, reasons to invest, and valuation.

Watch InvestSeekers on YouTube

Follow me on X

I also share more frequent investment updates on X, including company news, new analyses, and changes I make to my portfolio.

Follow me on X

A cause I support

If you found my analysis valuable and would like to support a good cause, I encourage you to consider making a small donation to ADEPAC. It is a charity I know firsthand, and I have seen the valuable work they do despite having very limited resources.

Even a small donation can make a difference.

Support ADEPAC